Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
The subscription price for warrants of series TO 3 has been set at SEK 3.78 per share
PHI announces that the subscription price for warrants of series TO 3 has been set at SEK 3.78 per share.
Clarification Regarding Potential Collaborations
Thi information is provided to mitigate any misinterpretation of the information unintentionally made publicly after a PHI presentation at a CERN Knowledge Transfer Seminar held on March 27, 2023.
Notice that Interim Report 3 2022/23 will be published already on March 28, 2023
PHI changes the date for publication of Interim Report 3 2022/23 to March 28, 2023.
PHI creates a subsidiary for the anticipated EU patent concerning synthetic antibodies
PHI has decided to create a dedicated subsidiary to house the synthetic antibody patent family and facilitate its business potential.
Swiss-based Altium acquires major stake in PHI
PHI announces that Altium S.A. recently acquired Formue Nord’s entire holdings in PHI of 2 416 679 shares and 1 491 362 TO 3 warrants and committed to exercise the obtained warrants.
PHI expands its global network to India
PHI has entered a business relationship with Medi Analytika India Pvt. Ltd. This new distributor will represent PHI in the large and growing Indian market and manage the full sales process and customer relations for the HoloMonitor® product portfolio.
PHI Focuses on Biomanufacturing — Appoints New CEO and Chairman
The Board of Directors of PHI has appointed the company’s CFO, Patrik Eschricht, as the new CEO. In addition, the former CEO and founder of PHI, Peter Egelberg, has been appointed executive chairman of the Board.
PHI Is Opening A New Development Office In The US
As a result of the newly created alliance for advancing cell-based biomanufacturing which was recently communicated, PHI is taking the next step in its investment into regenerative medicine by opening an office in the Innovation Quarter in Winston-Salem.
PHI, SAS, QIAGEN and BioSpherix form Alliance to Advance Cell-based Biomanufacturing
In association with the Wake Forest Institute for Regenerative Medicine, PHI, BioSpherix, analytics leader SAS and QIAGEN have created a technology development alliance to create the AI-based process control tools needed for automated biomanufacturing.
Wake Forest Institute for Regenerative Medicine Welcomes PHI
PHI visits the WFIRM to finalize an agreement concerning the automation of advanced quality control in large-scale biomanufacturing of regenerative therapies.